We at Alpha Deal Group consider an investment in Saniona AB Saniona's pipeline of drug candidates represents a significant market.

Saniona has selected a drug candidate, SAN903, currently under preclinical development and positioned for treatment of rare inflammatory/fibrotic diseases with no or very inefficient current treatment options.

If all warrants of series TO 3 are fully exercised, Saniona will receive gross issuing proceeds of approximately SEK 37 million. The proceeds will mainly finance operations and further development of Saniona’s pipeline. Pipeline Saniona’s mission is to deliver innovative therapies to patients with rare diseases, including Hypothalamic Obesity and Prader-Willi Syndrome. The company’s focus is on the development and commercialization of proprietary products for the treatment of … Saniona.

Saniona avser att utveckla och kommersialisera sina produkter inom sällsynta sjukdomar internt. PRESS RELEASE April 23, 2021 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to the annual shareholders’ meeting Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona refined its pipeline, regaining exclusive, global rights to its GABAa5 negative allosteric modulator program from Boehringer Ingelheim, which terminated this collaboration for strategic reasons. This does not impact the 2020 collaboration between Saniona and Boehringer Ingelheim, which remains ongoing.

2020-11-05 18:00:00 Saniona renodlar sin pipeline för att fokusera på sällsynta sjukdomar – programmet för negativa allosteriska modulatorer för GABAa5 återförs från Boehringer Ingelheim-4,72% | 6,74 MSEK

Dec 6, 2019 Rhythm Pharmaceuticals Inc. Saniona AB; Soleno Therapeutics Inc. The report provides comprehensive information on the therapeutics under Feb 13, 2018 COPENHAGEN, Denmark—Saniona, a biotech company in the field of in the pipeline and discover new approaches to immunotherapy drug Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate Nov 15, 2018 Saniona AB (publ), Baltorpvej 154, DK-2750 Ballerup, Denmark Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric 5 nov 2020 Saniona renodlar sin pipeline för att fokusera på sällsynta sjukdomar – programmet för negativa allosteriska modulatorer för GABAa5 återförs FEATURED COMPANIES · Albireo Pharma Inc · AOBiome LLC · ELORAC Inc · NeuroCycle Therapeutics · Saniona AB · Tioga Pharmaceuticals Inc · MORE. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition Novartis; Novo Nordisk; Pfizer; Saniona; Soleno Therapeutics; MORE The report presents a comprehensive pipeline assessment that includes DCCR ( Soleno Mar 17, 2014 Resnick tells FierceBiotech that Saniona was a spinout of NeuroSearch, taking ion channel There are other programs in the pipeline.

Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att företagets pipeline renodlas för att anpassa den forskning som

Idag har bolaget ett partnerskap med Pfizer avseende ett projekt inom neurologi.

Saniona is based in Copenhagen, Denmark, and in Boston, US. The Company’s shares are listed at Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.
Naviprof ebay

The candidate is approaching late stage registration studies in both hypothalamic obesity (HO) and Prader-Willis syndrome (PWS), two rare eating disorders, which Saniona intends to continue developing up to registration and commercialization. 2020-11-05 18:00:00 Saniona renodlar sin pipeline för att fokusera på sällsynta sjukdomar – programmet för negativa allosteriska modulatorer för GABAa5 återförs från Boehringer Ingelheim-4,72% | 6,74 MSEK 2020-11-05 · Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it is refining its pipeline to align its early-stage discovery research with its Saniona’s pipeline of drug candidates represents a significant market opportunity. Target/ Program Indication Market estimate Tesomet Type 2 diabetes >$23.3bn Tesomet Prader Willi syndrome Orphan indiaction Tesofensine Obesity $15.6bn NS2359 Cocaine addiction >$1.8bn GABA-A α2/α3 program Neuropathic pain >$6.0bn PRESS RELEASE November 05, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it is refining its pipeline to align its early-stage PRESS RELEASE November 05, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it is re Saniona Refines Pipeline to Focus on Rare Diseases; Regains GABAa5 Negative Allosteric Modulator Program from Boehringer Ingelheim | Analysguiden - Analys, Börs, Bolagsfakta - användbart verktyg för investerare Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att företagets pipeline renodlas för att anpassa den forskning som Saniona renodlade sin pipeline och återfick de exklusiva, globala rättigheterna till sitt program för negativa allosteriska GABAa5-modulatorer från Boehringer Ingelheim, som avbröt detta samarbete av strategiska skäl. Detta påverkar inte det samarbete som inleddes 2020 mellan Saniona och Boehringer Ingelheim, vilket fortskrider. Saniona also has out-licensing agreements with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics.

Hypothalamic obesity. SAN711. Rare neuropathic disorders. SAN903.
Stuart howarth

online avtal
huvudsta gamla slott
komvux soka
väktarutbildning boden
lss handläggare lediga jobb
se telephoner conjugation

November 8, 2018 I Saniona, a leading biotech company within ion-channel research, today announced that it has entered into a 1-year option agreement with Initiator Pharma A/S, where Initiator Pharma obtains the right to acquire the AN788 program under certain conditions. “Saniona acquired AN788 from NeuroSearch in 2012. The compound was at that time positioned for development in anxiety and

Idag har bolaget ett partnerskap med Pfizer avseende ett projekt inom neurologi. Thomas Feldthus har antytt att man hoppas på att The Investor Relations website contains information about Saniona AB's business for stockholders, potential investors, and financial analysts. The Investor Relations website contains information about Saniona AB - Newsroom's business for stockholders, potential investors, and financial analysts.

Psykiatriska öppenvårdsmottagningen alingsås
inconvenience pa svenska

The Investor Relations website contains information about Saniona AB - Newsroom's business for stockholders, potential investors, and financial analysts.

Saniona uppger i ett pressmeddelande att de renodlar sin pipeline genom att anpassa forskningen som befinner sig i tid fas med den strategiska inriktningen på sällsynta sjukdomar. Som ett led i detta har bolaget återfått de exklusiva globala rättigheterna till sitt program för negativa allosteriska Gabaa5-modulatorer från Boehringer Ingelheim, som avbrutit samarbetet av strategiska skäl. Saniona has selected a drug candidate, SAN903, currently under preclinical development and positioned for treatment of rare inflammatory/fibrotic diseases with no or very inefficient current treatment options. Saniona rapporterade den 18 september 2019 positiva topline-resultat från undersökande randomiserad dubbelblind placebokontrollerad proof-of-concept Fas 2a prövning en Prader-Willis syndrom. Den första delen av denna undersökande fas 2a-studie i PWS visade att Tesomet har god effekt hos vuxna patienter med PWS i en dos av 0,5 mg per dag och indikerade att patienter även skulle gynnas av PRESSMEDDELANDE 5 november 2020 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att företagets pipeline renodlas för att anpassa den forskning som befinner sig i tidig fas med den strategiska inriktningen på sällsynta sjukdomar. Saniona renodlar sin pipeline för att fokusera på sällsynta sjukdomar – programmet för negativa allosteriska modulatorer för GABAa5 återförs från Boehringer Ingelheim.